Second-line chemotherapy with irinotecan and vinorelbine in stage IIIb and IV non-small-cell lung cancer: A phase II study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 5, 2002, Pages 480-484

  González Cao, María ^a   Aramendía, Jose Manuel ^a   Salgado, Esteban ^a   Aristu, Javier ^a   Martínez Monje, Rafael ^a   Algarra, Salvador Martín ^a   Ordoñez, Jose Manuel ^a   Brugarolas, Antonio ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Irinotecan; Lung cancer; Second line treatment; Vinorelbine

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN; GEMCITABINE; IRINOTECAN; LOPERAMIDE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PNEUMONIA; PROGNOSIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 0036795151     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200210000-00012     Document Type: Article

References (31)

1. Rapp E, Pater JL, Willian A, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633-41.
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;331:899-909.
3. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11:1866-72.
4. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small-cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
5. Luedke DW, Einhorn L, Omura GA, et al. Randomized comparison of two combination regimens versus minimal chemotherapy in non-small cell lung cancer: a Southeastern Cancer Study Group trial. J Clin Oncol 1990;8:886-91.
6. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-26.
7. Le Chevalier T, Brisgand D, Douillard JK, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1999;12:360-7.
8. Sorensen JB, Stenbygaard LE, Dombernowsky P, et al. Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer. Ann Oncol 1999;10:1043-9.
9. Hainsworth JD, Burris HA 3rd, Litchy S, et al. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients. Cancer 2000;88:1353-8.
10. Shepherd FA. Chemotherapy for non-small cell lung cancer: have we reached a new plateau? Semin Oncol 1999;26:3-11.
11. Nakanishi Y, Takayama K, Takano K, et al. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am J Clin Oncol 1999;22:399-402.
12. Fosella F, Rigas J. The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. Semin Oncol 1999;26:S9-12.
13. Georgoulias V, Kourousis C, Kakolyris S, et al. Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen. Semin Oncol 1997;24:S12-66.
14. Ruckdeschel J, Wagner H, Williams C, et al. Second line chemotherapy for resistant, metastatic non-small-cell lung cancer. The role of Taxol. Proc ASCO 1994;357.
15. Crino L, Mosconi AM, Scagliotti GV, et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1999;17:2081-5.
16. Fossella FV, DeVore R, Kerr RN. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354-62.
17. Shepherd A, Dancey J, Ramlau R. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
18. Rothemberg ML. CPT-11: an original spectrum of clinical activity. Semin Oncol 1996;23:S21-6.
19. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivate of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992;10:16-20.
20. Nakai H, Fukuoka M, Furuse K, et al. An early phase II study of CPT-11 for primary lung cancer. Jpn J Cancer Chemother 1991;18:607-12.
21. Niitani H, Fukuoka M, Nagao K. Clinical development of irinotecan (CPT-11) in lung cancers. Lung Cancer 1994;11:S30-1.
22. Negoro S, Fukuoka M, Niitani H, et al. A phase II study of CPT-11, a camptothecin derivate, in patients with primary lung cancer. CPT-11 cooperative study group. Gan To Kagaku Ryoho 1991;18:1013-9.
23. Fujita A, Takabatake H, Tagaki S, et al. Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer. Oncology 1999;56:301-7.
24. Mori K, Machida S, Yoshida T, et al. A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 1999;43:467-70.
25. Wozniak AJ. Single-agent vinorelbine in the treatment of non-small cell lung cancer. Semin Oncol 1999;26:S62-6.
26. Mogi H, Hasegawa Y, Watanabe A, et al. Combination effects of cisplatin, vinorelbine and irinotecan in non-small-cell lung cancer cell lines in vitro. Cancer Chemother Pharmacol 1997;39:199-204.
27. Rodriguez J, Cortes J, Calvo E, et al. Paclitaxel, cisplatin and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma. Cancer 2000;12:2622-9.
28. World Health Organization. WHO handbook for Reporting Results of Cancer Treatment (WHO Offset Publication No. 48). Geneva, Switzerland: World Health Organization, 1979.
29. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
30. Santoro A, Maiorino L, Santoro M. Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small cell lung cancer. Lung Cancer 1994;11:S130.
31. Chang AY, DeVore R, Jonhson D. Pilot study of vinorelbine (Navelbine) and paclitaxel in patients with refractory non-small cell lung cancer. Semin Oncol 1996;23:S19-21.